A
Arghya Ray
Researcher at Harvard University
Publications - 72
Citations - 4451
Arghya Ray is an academic researcher from Harvard University. The author has contributed to research in topics: Bortezomib & Multiple myeloma. The author has an hindex of 28, co-authored 64 publications receiving 4008 citations. Previous affiliations of Arghya Ray include University of California, Los Angeles & Brigham and Women's Hospital.
Papers
More filters
Journal ArticleDOI
Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl
Ellen Weisberg,Paul W. Manley,Werner Breitenstein,Josef Brüggen,Sandra W. Cowan-Jacob,Arghya Ray,Brian J. P. Huntly,Doriano Fabbro,Gabriele Fendrich,Elizabeth Hall-Meyers,Andrew L. Kung,Andrew L. Kung,Jürgen Mestan,George Q. Daley,Linda Callahan,Laurie Catley,Cara Cavazza,Azam Mohammed,Donna Neuberg,Renee D. Wright,D. Gary Gilliland,James D. Griffin +21 more
TL;DR: AMN107 prolonged survival of mice injected with Bcr-Abl-transformed hematopoietic cell lines or primary marrow cells, and prolonged survival in imatinib-resistant CML mouse models, suggests this is a promising new inhibitor for the therapy of CML and Ph+ ALL.
Journal ArticleDOI
AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL.
Ellen Weisberg,Paul W. Manley,Jürgen Mestan,Sandra W. Cowan-Jacob,Arghya Ray,James D. Griffin +5 more
TL;DR: In this review, the early characterisation and development of AMn107 is discussed, as is the current status of AMN107 in clinical trials for imatinib-resistant CML and Ph+ ALL.
Journal ArticleDOI
A novel small molecule inhibitor of deubiquitylating enzyme USP14 and UCHL5 induces apoptosis in multiple myeloma and overcomes bortezomib resistance.
Ze Tian,Padraig D'Arcy,Xin Wang,Arghya Ray,Yu-Tzu Tai,Yiguo Hu,Ruben D. Carrasco,Paul G. Richardson,Stig Linder,Dharminder Chauhan,Kenneth C. Anderson +10 more
TL;DR: Preclinical data showing efficacy of b-AP15 in MM disease models validates targeting DUBs in the ubiquitin proteasomal cascade to overcome proteasome inhibitor resistance and provides the framework for clinical evaluation of USP14/UCHL5 inhibitors to improve patient outcome in MM.
Journal ArticleDOI
Targeting PD1–PDL1 immune checkpoint in plasmacytoid dendritic cell interactions with T cells, natural killer cells and multiple myeloma cells
Arghya Ray,Deepika Sharma Das,Yan Song,Paul G. Richardson,Nikhil C. Munshi,D Chauhan,Kenneth C. Anderson +6 more
TL;DR: Targeting PD1–PDL1 immune checkpoint in plasmacytoid dendritic cell interactions with T cells, natural killer cells and multiple myeloma cells is targeted.
Journal ArticleDOI
Identification of BCR-ABL point mutations conferring resistance to the Abl kinase inhibitor AMN107 (nilotinib) by a random mutagenesis study
TL;DR: Interestingly, most AMN107-resistant mutants were also resistant to imatinib mesylate, which may predict some of the resistance mutations that will be detected in clinical trials with this kinase inhibitor.